Gold sponsor

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. By far, XellSmart has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including:

Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease;

Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class);

and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class, designated as an Orphan Drug by the U.S. FDA).

XellSmart has established a fully dedicated, internationally competitive "All-In" team and has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place.

Website: www.xellsmart.com

« Go Back